Lusaris Therapeutics, a Boston, MA-based biotechnology company, raised $60M in Series A financing.
The round was led by RA Capital Management, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, and Boxer Capital.
The company intends to use the funds to further develop its health solutions, expand operations and its business reach.
Led by CEO Andrew Levin and Chief Operating Officer Neil Buckley, Lusaris Therapeutics is a biotechnology company advancing serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. Its lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, an acting and clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. In addition to LSR-1019, the company’s pipeline includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions including migraine and cluster headache.
Lusaris is also announcing it has entered into a strategic collaboration with Catalent under which Lusaris has been granted an exclusive worldwide license to Catalent’s Zydis fast-dissolving tablet technology for the 5-MeO-DMT program.
The company’s leadership team includes Andrew Levin, M.D., Ph.D., Interim Chief Executive Officer; Neil Buckley, M.S., Chief Operating Officer; Ed Monaghan, Ph.D., Chief Development Officer; Ramin Farzaneh-Far, M.D., Acting Chief Medical Officer; Kat Riesen, CPA, Chief Financial Officer; Ned Whittemore, Ph.D., Vice President, Regulatory Affairs; Matt Harding, Ph.D., Vice President, Discovery; K. George Mooney, Ph.D., Vice President, CMC; and Daniel Grau, MPhil, Chairman of the Board of Directors.
FinMSEs
07/11/2022